• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Inotek recalibrates after drug fails in glaucoma trial

July 10, 2017 By Sarah Faulkner

Inotek PharmaInotek Pharmaceuticals (NSDQ:ITEK) said last week that its glaucoma drug failed in a Phase II trial. This marks the 2nd problem for Inotek’s drug this year, after it failed in a late-stage trial comparing it to a placebo in January.

In response to the data, CEO David Southwell said in a statement that the company is assessing the future of its drug, trabodenoson, and “other strategic options.”

The Lexington, Mass.-based company’s Phase II trial enrolled 201 patients and studied trabodenoson with Xalatan, or latanoprost. Inotek was looking for its compound to demonstrate an improvement in intraocular pressure over the course of the 2-month trial. The company tested 3 doses combinations of trabodenoson and Xalatan.

Although patients who received the combination therapy experienced improvement compared to latanoprost alone, the effect was not lasting. By day 56, the intraocular pressure in patients who received just latanoprost had improved by 1.3 mmHg, while those treated with the combination didn’t experience any benefit.

The company has brought on Perella Weinberg Partners to serve as a financial advisor while Inotek reviews its options.

ITEK shares plummeted today, trading down -50% at 90¢ apiece in afternoon activity.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: inotekpharmaceuticals

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS